When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

LOS ANGELES, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Stride, Inc. (“Stride” or “the Company”) (NYSE: LRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 12, 2026.

SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Davis Commodities Limited (“Davis Commodities” or the “Company”) announced that it is evaluating a strategic scale-up framework for China and North Asia, supported by the assessment of sugar-based, value-added sweeteners positioned for expanding consumption channels and industrial food applications. This initiative forms part of the Company's ongoing review of potential downstream integration opportunities, regional diversification strategies, and pathways to build scalable, higher-value growth platforms.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Inspire Medical to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 29, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical …

XPeng launches G9 and G6 SUVs in Qatar, expanding its Middle East and Africa footprint through partnerships and new infrastructure.

IT shares have risen 8.6% over the past month as research strength, AI-driven AskGartner, conferences and steady buybacks support growth despite liquidity risks.

Microsoft (MSFT) sits at the heart of the AI revolution heading into 2026, with Azure and AI-driven services powering unprecedented growth momentum. Trading around $490 as of late December 2025, up 16% in 2025, the stock carries a forward P/E of roughly 31x based on fiscal 2026 earnings estimates of $15.75 per share.

LOS ANGELES, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the "Company") (NASDAQ: SKYE) investors of a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion.

Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.

SANM, GLDD and CMC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 29, 2025.

WDC looks more balanced than STX as AI and cloud fuel storage demand, with lower valuation, rising margins and multi-year HDD contracts despite risks.